The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
AACR 2017 | Poster 2033/5 – Testing the combined effects of low dose olaparib plus ibrutinib on Mantle Cell Lymphoma cytotoxicity
On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2033 / 5) by Adam D. Curtis, from the Eastern Maine Medical Center, Brewer, ME, et al. titled “Testing the combined effects of low dose olaparib plus ibrutinib on MCL cytotoxicity” was presented.
The group aimed to potentially improve ibrutinib therapy for MCL by combining it with olaparib, a DNA damage response inhibitor, and testing the combination in MCL cells in vitro.
Key Highlights:
- Ibrutinib monotherapy is cytotoxic to MCL cell lines but only at high doses (>25μM)
- MCL growth is more sensitive to olaparib that ibrutinib
- Olaparib monotherapy treatment is cytotoxic to MCL cell lines at lower concentrations (10μM) than ibrutinib
- Low doses of ibrutinib combined with olaparib inhibited MCL cell growth more than either drug alone at concentrations <EC50
- The ibrutinib-olaparib combination increases apoptosis and MCL cell death
The poster was concluded by hypothesizing that ibrutinib combined with olaparib potentially could improve response rate and duration in patients with MCL, as well as reducing adverse events.
References